What the Prolia TV commercial - Dog Wash is about.
Title: Prolia TV Spot, 'Dog Wash'
: "Introducing the Prolia Dog Wash Event!"
: "At Prolia, we care about more than just your health. We care about the whole you, including your furry friends!"
: "Prolia is a treatment for osteoporosis that helps strengthen bones and reduce the risk of fractures."
: "With Prolia, you can stay active and enjoy every moment with your four-legged companions."
: "So why wait? Talk to your healthcare provider about Prolia today!"
: "Prolia: Caring for you and your furry family members. Together, we can lead healthier, happier lives."
[Fade out.]
[Disclaimer: Professional medical advice should always be sought before beginning any medication.]
End of TV Spot
Note: This fictional TV spot script aims to promote Prolia, a bone-strengthening medication, through a heartwarming event. The focus is on the importance of overall well-being, including the bond between humans and their pets. The script highlights the community feel of the Prolia Dog Wash, while introducing the medication's benefits for managing osteoporosis and promoting an active lifestyle.
Prolia TV commercial - Dog Wash produced for
Prolia
was first shown on television on May 11, 2021.
Frequently Asked Questions about prolia tv spot, 'dog wash'
Delayed injection
This causes a sudden drop in bone density and increases your risk of spinal fractures. You can have repeat injections up to four weeks early, so you have some flexibility.
Prolia can treat osteoporosis and bone loss only for as long as you keep having treatment. Please talk to your doctor before you consider stopping treatment. If you miss a dose, it should be administered as soon as possible. From then on, it should be scheduled every 6 months from the date of the last injection.
Prolia® has a shelf life of 36 months and may be stored at room temperature (25°C) for up to 30 days in the original container. Once removed from the refrigerator it must be used within this 30 day period1. Prolia® is indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fractures.
The recommended doses of denosumab are at 6-month intervals. Patients who delayed a dose by more than 16 weeks were nearly four times more likely to suffer vertebral fractures, compared with those who received on-time injections, according to the study, which was published in Annals of Internal Medicine.
Missed dose
If you miss a Prolia injection, call your doctor or the place where you receive your injections as soon as you can. They'll help reschedule your missed dose for as soon as possible. And, they'll make sure your next scheduled dose is still 6 months away (or however often you receive Prolia injections).
It can be given any time with or without food by a healthcare professional, by a trained injector, or a patient may self-inject if a healthcare professional determines that it is appropriate. Your prefilled syringe may be left outside the refrigerator to reach room temperature (up to 25°C) before injection.
Keep the prefilled syringe in the original carton to protect from light or physical damage. Take the prefilled syringe out of the refrigerator 15 to 30 minutes before use and allow it to reach room temperature before preparing an injection.
After your treatment with Prolia® is stopped, or if you skip or delay taking a dose, your risk for breaking bones, including bones in your spine, is increased. Your risk for having more than 1 broken bone in your spine is increased if you have already had a broken bone in your spine.
After your treatment with Prolia® is stopped, or if you skip or delay taking a dose, your risk for breaking bones, including bones in your spine, is increased. Your risk for having more than 1 broken bone in your spine is increased if you have already had a broken bone in your spine.
Stopping Prolia can cause an increase in the number of multiple vertebral fractures often within a year of stopping. The reason for this is once Prolia injections stop there is an increase in bone turnover and rapid bone resorption.
The U.S. Food and Drug Administration (FDA) is investigating the risk of severe hypocalcemia with serious outcomes, including hospitalization and death, in patients with advanced kidney disease on dialysis treated with the osteoporosis medicine Prolia (denosumab).
The recommended doses of denosumab are at 6-month intervals. Patients who delayed a dose by more than 16 weeks were nearly four times more likely to suffer vertebral fractures, compared with those who received on-time injections, according to the study, which was published in Annals of Internal Medicine.